HNSCC subverts PBMCs to secrete soluble products that promote tumor cell proliferation

Nenhuma Miniatura disponível

Data

2017-09-05

Autores

Medeiros, Marcell Costa de [UNESP]
Banerjee, Rajat
Liu, Min
Anovazzi, Giovana [UNESP]
D'Silva, Nisha J.
Rossa, Carlos [UNESP]

Título da Revista

ISSN da Revista

Título de Volume

Editor

Impact Journals Llc

Resumo

The immune system detects shifts from homeostasis and eliminates altered cells. However, neoplastic cells can modulate the host response to escape immunosurveillance thereby allowing tumor progression. Head and neck squamous cell carcinoma (HNSCC) is one of the most immunosuppressive cancers but its role in co-opting the immune system to actively promote tumor growth has not been investigated. In this study, we investigated the influence of soluble factors secreted by HNSCC and non-neoplastic epithelial cells on proliferation, apoptosis, activation, cytokine gene expression and phenotypic polarization of immune cells of healthy donors. Then, we determined if the immunomodulation caused by HNSCC-derived soluble products leads to immunosubversion by assessing proliferation, migration and survival of tumor cells exposed to soluble products secreted by modulated immune cells or co-cultured with immune cells. Soluble products from HNSCC inhibited proliferation and cytokine expression in PBMCs, activation of T cells, and polarization of CD4+ towards the Th17 phenotype. These changes co-opted the immune cells to favor cell proliferation, survival and migration of HNSCC. This immunosubversion was observed both indirectly with secreted products and with direct cell-to-cell contact. We conclude that HNSCC-derived secreted products create an immunosuppressive environment that facilitates evasion of tumor cells and subverts the immune cells into a pro-tumoral phenotype.

Descrição

Palavras-chave

head and neck squamous cell carcinoma, immune response, T cell, immunosuppression and tumor scape, Immunology and Microbiology Section, Immune response, Immunity

Como citar

Oncotarget. Orchard Park: Impact Journals Llc, v. 8, n. 37, p. 60860-60874, 2017.